Trial Profile
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Jul 2019 Status changed from recruiting to discontinued.
- 27 Mar 2018 Planned number of patients changed from 58 to 62.
- 07 Feb 2017 New trial record